Precipio (NASDAQ:PRPO) Shares Cross Below Two Hundred Day Moving Average of $1.20

Precipio, Inc. (NASDAQ:PRPOGet Rating) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.20 and traded as low as $0.86. Precipio shares last traded at $0.89, with a volume of 103,768 shares trading hands.

Precipio Price Performance

The stock has a fifty day moving average of $1.21 and a 200-day moving average of $1.19. The company has a quick ratio of 2.04, a current ratio of 2.19 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $17.73 million, a price-to-earnings ratio of -1.70 and a beta of 2.09.

Institutional Investors Weigh In On Precipio

A hedge fund recently bought a new stake in Precipio stock. Great Valley Advisor Group Inc. acquired a new stake in Precipio, Inc. (NASDAQ:PRPOGet Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,100 shares of the biotechnology company’s stock, valued at approximately $35,000. Great Valley Advisor Group Inc. owned 0.15% of Precipio at the end of the most recent quarter. Institutional investors and hedge funds own 9.79% of the company’s stock.

About Precipio

(Get Rating)

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests.

Read More

Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.